Skip to main content
Top
Published in: Reactions Weekly 1/2008

01-03-2008 | Clinical study

Continuous oral contraception does not reduce the number of bleeding days over a 168-day period

Published in: Reactions Weekly | Issue 1/2008

Login to get access

Excerpt

Continuous oral contraception does not reduce the number of bleeding days over a 168-day period, compared with traditional cyclical contraception, according to a US study. This study involved 62 women with regular menses who were randomised to receive either continued 4-week cycles of 28 active pills with ethinylestradiol/norethisterone 20µg/1mg or 21 active pills of the same formulation followed by 7 placebo pills. The number of total bleeding days was similar in the group receiving continuous contraception, compared with that receiving cyclical contraception (31.5 vs 35.1 days). However, there was a significant decrease in moderate/heavy bleeding days with continuous contraception (5.2 vs 11.0 days). Continuous contraception also provided greater suppression of the ovary and endometrium. …
Literature
1.
go back to reference Legro RS, Pauli JG, Kunselman AR, Meadows JW, Kesner JS, Zaino RJ, Demers LM, Gnatuk CL, Dodson WC.Effects of continuous versus cyclical oral contraception: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 93: 420-429, No. 2, Feb 2008 Legro RS, Pauli JG, Kunselman AR, Meadows JW, Kesner JS, Zaino RJ, Demers LM, Gnatuk CL, Dodson WC.Effects of continuous versus cyclical oral contraception: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 93: 420-429, No. 2, Feb 2008
Metadata
Title
Continuous oral contraception does not reduce the number of bleeding days over a 168-day period
Publication date
01-03-2008
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2008
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-200811940-00011

Other articles of this Issue 1/2008

Reactions Weekly 1/2008 Go to the issue

Case report

Folic acid

Case report

Budesonide

Case report

Immunotherapies

Case report

Diclofenac